Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 in Moderately to Severely Active Ulcerative Colitis
NCT07577856Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of guselkumab + golimumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
guselkumab + golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07577856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577856.